Since the two cell lines are identical except for the presence of the transgene, and there is clear evidence in the literature that neither of these cell lines are very immunogenic when inoculated into normal WT mice [15], our results strongly indicate, that availability of tumor-targeting T-cell repertoire signifies a key factor in deciding the clinical effectiveness of combination therapy with anti-4-1BB and anti-CTLA-4